What is Adimab?
Adimab operates at the forefront of biopharmaceutical innovation, offering a sophisticated yeast-based platform for the discovery and engineering of therapeutic antibodies. The company's comprehensive services span antibody discovery, optimization, and the development of multispecific antibodies, all designed to accelerate the creation of novel treatments and improve patient outcomes. With a robust history of over 140 biopharma partnerships, Adimab has demonstrated a consistent ability to advance therapeutic programs through flexible collaboration models. Founded in 2007, the company's sustained growth and industry recognition highlight its pivotal role in the biopharma ecosystem.
How much funding has Adimab raised?
Adimab has raised a total of $32M across 4 funding rounds:
Series A
$6M
Series D
$8.2M
Series E
$4M
Series F
$13.8M
Series A (2007): $6M with participation from SV Health Investors and Polaris Partners
Series D (2010): $8.2M led by OrbiMed, Google Ventures, SV Life Sciences, Borealis Ventures, and Polaris Partners
Series E (2010): $4M, investors not publicly disclosed
Series F (2012): $13.8M featuring Google Ventures, SV Life Sciences, and Polaris Partners
Key Investors in Adimab
Google Ventures
GV is a venture capital firm founded in 2001 that invests across multiple stages and sectors, focusing on enterprise solutions, life sciences, consumer products, and frontier technology innovations. GV operates globally, providing financial backing to promising startups and growth-stage businesses.
SV Life Sciences
SV Health Investors is a specialist investment firm backing innovative health care and life science companies, partnering with founders and management to provide capital, sector expertise and active support from early growth through scale and value creation.
Polaris Partners
Polaris Partners is a venture capital firm that specializes in backing transformational companies in the biotech and healthcare sectors, providing coaching, advice, and resources for growth. Their team consists of board members, entrepreneurs, scientists, and operators who engage deeply to foster innovation and collaboration.
What's next for Adimab?
The substantial enterprise-level funding Adimab has garnered, including its latest strategic investment, signals a strong confidence from its backers in the company's future trajectory. This capital infusion is expected to fuel further research and development, enhance its proprietary discovery platform, and potentially expand its market reach. Adimab's ongoing commitment to flexible collaboration models suggests a strategic focus on deepening existing partnerships and forging new alliances to bring innovative antibody therapeutics to market more efficiently. The company appears poised for a significant scaling phase, leveraging its established expertise and strong financial backing to address unmet medical needs.
See full Adimab company page
